BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America. To come up with this list, BioSpace evaluated companies that launched between September 2021 and September 2022 with Series A funding. They were then assessed using several different criteria and ranked […]
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
Study Rationale: Parkinson’s disease (PD) is associated with activating mutations in a protein kinase called LRRK2. In previous studies, we found that regulating LRRK2’s chemical modification by phosphorylation controls the inappropriate activation of the protein. Because LRRK2 phosphorylation is decreased in PD, we propose that enhancing LRRK2 phosphorylation at key sites on the protein will
Michael J. Fox Foundation for Parkinson’s Research Read More »
SAN FRANCISCO, Calif., April 25, 2022 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board. Dr. Bollag brings extensive experience in structure-based drug discovery and the development of oncology therapeutics. “This is a perfect moment to welcome Gideon
Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board Read More »
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value targets in oncology SAN FRANCISCO, Calif., January 06, 2022 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment